Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single‐agent therapy. Eventually, 30% of patients with MDS will progress and develop acute myeloid leukemia (AML). New strategies are needed for these patients.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  J. Byrd,et al.  Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .

[3]  Pablo Tamayo,et al.  An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome , 2008, PLoS medicine.

[4]  Shaji K. Kumar,et al.  Drug Insight: thalidomide as a treatment for multiple myeloma , 2005, Nature Clinical Practice Oncology.

[5]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[6]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[7]  R. Fanin,et al.  Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes , 2005, Annals of Hematology.

[8]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[9]  Jill P. Mesirov,et al.  Comparative gene marker selection suite , 2006, Bioinform..

[10]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[11]  C. Schiffer,et al.  Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. , 1990, Leukemia.

[12]  B. Hoogstraten,et al.  5‐azacytidine in acute leukemia , 1978, Cancer.

[13]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.